|
1) Yang YG, Dey BR, Sergio JJ, et al. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. J Clin Invest. 1998; 102: 2126-35
|
|
|
|
2) Murphy WJ, Welniak LA, Taub DD, et al. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest. 1998; 102: 1742-8
|
|
|
|
|
|
3) Welniak LA, Blazar BR, Anver MR, et al. Opposing roles of interferon-gamma on CD4＋ T cell-mediated graft-versus-host disease: effects of conditioning. Biol Blood Marrow Transplant. 2000; 6: 604-12
|
|
|
|
|
|
4) Reddy P, Teshima T, Kukuruga M, et al. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med. 2001; 194: 1433-40
|
|
|
|
|
|
5) Yi T, Chen Y, Wang L, et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft versus host disease. Blood. 2009; 114: 2858-9
|
|
|
|
|
|
6) Fowler DH, Kurasawa K, Smith R, et al. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood. 1994; 84: 3540-9
|
|
|
|
|
|
7) Tawara I, Maeda Y, Sun Y, et al. Combined Th2 cytokine deficiency in donor T cells aggravates experimental acute graft-vs-host disease. Exp Hematol. 2008; 36: 988-96
|
|
|
|
|
|
8) Fowler DH, Odom J, Steinberg SM, et al. Phase I clinical trial of costimulated, IL-4 polarized donor CD4＋ T cells as augmentation of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006; 12: 1150-60
|
|
|
|
|
|
9) Nikolic B, Lee S, Bronson RT, et al. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest. 2000; 105: 1289-98
|
|
|
|
|
|
10) Carlson MJ, West ML, Coghill JM, et al. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood. 2009; 113: 1365-74
|
|
|
|
|
|
11) Iclozan C, Yu Y, Liu C, et al. Th17 cells are sufficient but not necessary to induce acute qraft-versus-host disease. Biol Blood Marrow Transplant. 2009; online
|
|
|
|
|
|
12) Kappel LW, Goldberg GL, King CG, et al. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood. 2009; 113: 945-52
|
|
|
|
|
|
13) Das R, Chen X, Komorowski R, et al. Interleukin-23 secretion by donor antigen-presenting cells is critical for organ-specific pathology in graft-versus-host disease. Blood. 2009; 113: 2352-62
|
|
|
|
|
|
14) Yi T, Zhao D, Lin CL, et al. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood. 2008; 112: 2101-10
|
|
|
|
|
|
15) Meguro A, Ozaki K, Oh I, et al. IL-21 is critical for graft-versus-host disease in a mouse model. Bone Marrow Transplant. 2009; online
|
|
|
|
|
|
16) Bucher C, Jasperson L, Vogtenhuber C, et al. IL-21 blockade reduces graft-versus-host disese mortality by supporting inducible T regulatory cell generation. Blood. 2009; online
|
|
|
|
|
|
17) Givon T, Revel M, Slavin S. Potential use of inteleukin-6 in bone marrow tranpslantation: effects of recombinant human interleukin-6 after syngeneic and semiallogeneic bone marrow transplantation in mice. Blood. 1994; 83: 1690-7
|
|
|
|
|
|
18) Chen X, Das R, Komorowski R, et al. Blockade of interleukin-6 signaling augments regulatory T cell reconstitution and attenuates the severity of graft versus host disease. Blood. 2009; 114: 891-900
|
|
|
|
|
|
19) Chen X, Vodanovic-Jankovic S, Johnson B, et al. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood. 2007; 110: 3804-13
|
|
|
|
|
|
20) Chen X, Das R, Komorowski R, et al. Interlekin 17 is not required for autoimmune-mediated pathological damage during chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2009; online
|
|
|
|
|
|
21) Choi SW, Kitko CL, Braun T, et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood. 2008; 112: 1539-42
|
|
|
|
|
|
22) Levine JE, Paczesny S, Mineishi S, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood. 2008; 111: 2470-5
|
|
|
|
|
|
23) Toh HC, Sun L, Soe Y, et al. G-CSF induces a potentially tolerant gene and immunophenotype profile in T cells in vivo. Clin Immunol. 2009; 132: 83-92
|
|
|
|
|
|
24) Di Biaso I, Di Maio L, Bugarin C, et al. Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells. Transplantation. 2009; 87: 1422-5
|
|
|
|
|